Teleflex Incorporated (TFX)
$
138.19
+0.39 (0.28%)
Key metrics
Financial statements
Free cash flow per share
10.9953
Market cap
6.4 Billion
Price to sales ratio
2.0967
Debt to equity
0.4102
Current ratio
2.2655
Income quality
9.0492
Average inventory
620 Million
ROE
0.0156
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for various diagnostic and therapeutic procedures in critical care and surgical settings globally. The company recorded an operating income of $151,013,000.00 reflecting its earnings from core operations. It provides vascular access products that include Arrow branded catheters, catheter navigation and tip positioning systems, as well as intraosseous access systems for intravenous therapies, blood pressure measurement, and blood sample withdrawal through a single puncture site. The cost of revenue for the company is $1,344,645,000.00 showcasing its production and operational expenses. Additionally, the company earned an interest income of $8,009,000.00 showcasing its financial investments, while the net total of other income and expenses is -$75,535,000.00 reflecting non-core financial activities. Among its offerings are interventional products, which feature various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products utilized by interventional cardiologists, radiologists, and vascular surgeons, including Arrow branded catheters and the Manta Vascular Closure. The diluted EPS is $1.48 accounting for potential share dilution. Teleflex also supplies anesthesia products, surgical tools, interventional urology solutions, and respiratory care devices, catering to a diverse range of healthcare needs. The stock is reasonably priced at $136.61 appealing to a broad range of investors. With a mid-range market capitalization of $6,407,386,635.00 the company is a steady performer and belongs to the Healthcare sector, driving innovation and growth. Additionally, the stock has a low average trading volume of 1,067,083.00 indicating lower market activity, making it an intriguing option for investors. It is a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape while providing essential products and services to hospitals, healthcare providers, medical device manufacturers, and the home care market. As Teleflex continues to evolve, its strategic offerings are likely to maintain its presence within the healthcare sector, enhancing patient care and outcomes.
What is Teleflex Incorporated (TFX)'s stock forecast?
Analysts predict Teleflex Incorporated stock to fluctuate between $128.55 (low) and $249.91 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Teleflex Incorporated's market capitalization?
As of 2025-04-01, Teleflex Incorporated's market cap is $6,407,386,635, based on 46,366,500 outstanding shares.
How does Teleflex Incorporated compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Teleflex Incorporated has a Lower Market-Cap, indicating a difference in performance.
How can I buy Teleflex Incorporated (TFX) stock?
To buy Teleflex Incorporated (TFX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TFX. Place an order (Market, Limit, etc.).
What is the best time to invest in Teleflex Incorporated?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Teleflex Incorporated perform in the last earnings report?
Revenue: $3,047,324,000 | EPS: $1.49 | Growth: -80.34%.
Where can I find Teleflex Incorporated's investor relations reports?
Visit https://www.teleflex.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Teleflex Incorporated?
You can explore historical data from here
What is the all-time high and low for Teleflex Incorporated stock?
All-time high: $449.38 (2021-04-28) | All-time low: $128.55 (2025-03-03).
What are the key trends affecting Teleflex Incorporated stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
The addition to the IABP family supports uncompromised cardiac support for patients during transport The addition to the IABP family supports uncompromised cardiac support for patients during transport
prnewswire.com
NEW YORK , March 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE: TFX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
WAYNE, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that new findings from the CLEAR study were presented at the 40th Annual European Association of Urology (EAU) Congress in Madrid, which took place March 21-24, 2025. Among the results, the study showed better early patient satisfaction and sexual function with the UroLift™ System (PUL) compared to Rezūm™ Water Vapor Therapy (WVTT).1
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
prnewswire.com
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE: TFX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex Incorporated ("Teleflex Incorporated") (NYSE:TFX) concerning possible violations of federal securities laws. On February 27, 2025 the company announced that it was splitting off its Urology, Acute Care and OEM businesses into a new publicly traded company, the resignation of its CFO, and that it will acquire all of the vascular intervention business of BIOTRONIK SE for an estimated cash payment of about €760M, upon closing.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex Incorporated ("Teleflex Incorporated") (NYSE:TFX) concerning possible violations of federal securities laws. On February 27, 2025 the company announced that it was splitting off its Urology, Acute Care and OEM businesses into a new publicly traded company, the resignation of its CFO, and that it will acquire all of the vascular intervention business of BIOTRONIK SE for an estimated cash payment of about €760M, upon closing.
See all news
